Emerging drugs for treatment of anemia of chronic kidney disease

Bibliography

• Palmer SC, Navaneethan SD, Craig JC, et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med 2010;153(1):23-33
   PubMed Web of Science ®Google Scholar
• Fricke KL. Treatment of anemia in chronic kidney disease: past present, future. Medscape Nephrol 2006; Medscape Education Medscape, 21 Dec. 2006. Web. 3 June 2013
   Google Scholar
• Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339(9):584-90
   PubMed Web of Science ®Google Scholar
• Pfeffer M, Burdmann EA, Cooper DE, et al. A trial of darbepoetin-alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:1-14
   PubMedGoogle Scholar
• Paoletti E, Cannella G. Update on erythropoietin treatment: should hemoglobin be normalized in patients with chronic kidney disease? J Am Soc Nephrol 2006;17(4 Suppl 2):S74-7
   PubMed Web of Science ®Google Scholar
• Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007;369(9559):381-8
   PubMed Web of Science ®Google Scholar
• Leaf DE, Goldfarb DS. Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemia. Kidney Inter 2009;75:15-24
   PubMed Web of Science ®Google Scholar
• Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002;346(7):469-75
   PubMed Web of Science ®Google Scholar
• Bennett CL, Luminari S, Nissenson AR, et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med 2004;351(14):1403-8
   PubMed Web of Science ®Google Scholar
• Topf JM. CERA: third-generation erythropoiesis-stimulating agent. Expert Opin Pharmacother 2008;9(5):839-49
   PubMed Web of Science ®Google Scholar
• FDA. Briefing Document on Peginesatide for the Oncologic Drug Advisory Committee. December 7, 2011. Avaialbe from http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/oncologicdrugsadvisorycommittee/ucm282292.pdf [Last accessed 4 April 2012]
   Google Scholar
• Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003;4(8):459-60
   PubMed Web of Science ®Google Scholar
• Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362(9392):1255-60
   PubMed Web of Science ®Google Scholar
• Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299(8):914-24
   PubMed Web of Science ®Google Scholar
• Wilson J, Yao GL, Raftery J, et al. A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess 2007;11(13):1-202
   PubMed Web of Science ®Google Scholar
• Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009;373:1532-42
   PubMed Web of Science ®Google Scholar
• Glaspy J, Crawford J, Vansteenkiste J, et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer 2010;102:301-15
   PubMed Web of Science ®Google Scholar
• Tonelli M, Hemmelgarn B, Reiman T, et al. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ 2009;180:E62-71
   PubMed Web of Science ®Google Scholar
• Epogen package insert. Amgen, Inc. 2007. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/103234s5158ppi.pdf [Last accessed 5 February 2012]
   Google Scholar
• FDA Advisory Committee Briefing Document. Reassessment of the Risks of Erythropoiesis-Stimulating Agents (ESAs) Administered for the Treatment of Anemia associated with Chronic Renal Failure. Joint meeting of the Cardiovascular and Renal Drugs Advisory Committee and the Drug Safety and Risk Management Committee. 2007. Available from: http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4315b1-01-FDA.pdf [Last accessed 5 February 2012]
   Google Scholar
• Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 2008;26(1):132-49
   PubMed Web of Science ®Google Scholar
• European Medicines Agency, Science Medicines Health. Epoetin Alfa Hexal. 2009. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000726/human_med_000768.jsp&mid=WC0b01ac058001d125 [Last accessed 19 April 13]
   Google Scholar
• National Institute for Health and Clinical Excellence (NICE). Epoetin alfa, epoetin beta and darbepoetin alfa for cancer treatment-induced anaemia. National Institute for Health and Clinical Excellence (NICE); London (UK): 2008. p. 36; (Technology appraisal guidance; no. 142)
   Google Scholar
• Bren A, Kandus A, Varl J, et al. A comparison between epoetin omega and epoetin alfa in the correction of anemia in hemodialysis patients: a prospective, controlled crossover study. Artif Organs 2002;26(2):91-7
   PubMed Web of Science ®Google Scholar
• Singh AK, Szczech L, Tang KL, et al. CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-98
   PubMed Web of Science ®Google Scholar
• Goldsmith D. 2009: a requiem for rHuEPOs--but should we nail down the coffin in 2010? Clin J Am Soc Nephrol 2010;5(5):929-35
   PubMed Web of Science ®Google Scholar
• Mikhail A, Covic A, Goldsmith D. Stimulating erythropoiesis: future perspectives. Kidney Blood Press Res 2008;31:234-46
   PubMed Web of Science ®Google Scholar
• Rizzo J, Brouwers M, Hurley P, et al. American Society of Clinical Oncology/American Society of Hematology Clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncology 2010;28:4996-5010
   PubMed Web of Science ®Google Scholar
• Mikhail A. Profile of peginesatide and its potential for the treatment of anemia in adults with chronic kidney disease who are on dialysis. J Blood Med 2012;3:25-31
   PubMedGoogle Scholar
• Kathryn W, Woodburn KW, Christopher P, et al. Absorption, distribution, metabolism and excretion of peginesatide, a novel erythropoiesis-stimulating agent, in rats. Xenobiotica 2012;42(7):660-70
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Provenzano R, Sharma A, et al. Peginesatide for Anemia in Patients with Chronic Kidney Disease Not Receiving Dialysis. N Engl J Med 2013;368:320-32
   PubMed Web of Science ®Google Scholar
• Fishbane S, Schiller B, Locatelli F, et al. Peginesatide in Patients with Anemia Undergoing Hemodialysis. N Eng J Med 2013;368:307-19
   PubMed Web of Science ®Google Scholar
• Aapro M, Spivak JL. Update on erythropoiesis-stimulating agents and clinical trials in oncology. Oncologist 2009;14(Suppl 1):6-15
   PubMedGoogle Scholar
• Macdougall IC. New anemia therapies: translating novel strategies from bench to bedside. Am J Kidney Dis 2012;59(3):444-51
   PubMed Web of Science ®Google Scholar
• US FDA. Center for Drug Evaluation and Research. Cardiovascular and Renal Drugs Advisory Committee Meeting. 2010. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM238530.pdf [Last accessed 5 February 2012]
   Google Scholar
• US FDA. Center for Drug Evaluation and Research. Cardiovascular and Renal Drugs Advisory Committee Meeting. 2011. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM256586.pdf [Last accessed 5 February 2012]
   Google Scholar
• Mitka M. FDA sounds alert on anemia drug. JAMA 2007;297(17):1868-9
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration. Affymax and Takeda Announce a Nationwide Voluntary Recall of All Lots of OMONTYS® (peginesatide) Injection. February 25, 2013. Available from: http://www.fda.gov/Safety/Recalls/ucm340893.htm [Last accessed 6 April 2013]
   Google Scholar
• Burton T. Anemia drug had early side effect. Wall Street J 2013;B3
   Google Scholar
• Zhao S, Wu J. Hypoxia inducible factor stabilization as a novel strategy to treat anemia. Curr Med Chem 2013;20(21):2697-2711
   PubMed Web of Science ®Google Scholar
• Health Canada. Important Safety Information and New Prescribing Information for the Erythropoiesis-Stimulating Agents, Aranesp (darbepoetin alfa) and EPREX (epoetin alfa). 2007. Available from: http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/medeff/advisories-avis/public/2007/aranesp_eprex_pc-cp-eng.pdf [Last accessed 5 February 2012]
   Google Scholar
• Nangaku M, Kojima I, Tanaka T, et al. Novel drugs and the response to hypoxia: HIF stabilizers and prolyl hydroxylase. Recent Patent Rev Cardiovasc Drug Disc 2006;1:129-39
   PubMedGoogle Scholar
• Haase VH. Hypoxic regulation of erythropoiesis and iron metabolism. Am J Physiol Renal Physiol 2010;299:F1-F13
   PubMed Web of Science ®Google Scholar
• Astellas Pharma Inc. Adverse event of FG-2216 for the treatment of anemia. Media Release 2007. Available from: http://www.astellas.com/global/about/news/2007/pdf/070507_eg.pdf [Last accessed 15 October 2011]
   Google Scholar
• Porter RS. The merck manual of diagnosis and therapy. 19th edition. Wiley, John & Sons; 2011
   Google Scholar
• Arlet J, Hermine O, Darnige L, et al. Iron-Deficiency Anemia in Castleman Disease: implication of the Interleukin 6/Hepcidin Pathway. Peidatrics 2010;126(6):e1608-12
   Web of Science ®Google Scholar
• Firth HV, Hurst JA. Oxford desk reference: clinical genetics. 1st edition. Oxford University Press; 2005
   Google Scholar
• Imagawa S, Yamamoto M, Miura Y. Negative regulation of the erythropoietin gene expression by the GATA transcription factors. Blood 1997;89:1430-9
   PubMed Web of Science ®Google Scholar
• Brill-Almon E, Stern B, Afik D, et al. Ex vivo transduction of human dermal tissue structures for autologous implantation production and delivery of therapeutic proteins. Mol Ther 2005;12(2):274-82
   PubMed Web of Science ®Google Scholar
• Goldsmith DJ, Covic AC. Significant further evidence to bolster the link between epoetin and strokes in chronic kidney disease and cancer. Kidney Internat 2011;80:237-9
   PubMed Web of Science ®Google Scholar
• Elliott S, Pham E, Macdougall IC. Erythropoietins: a common mechanism of action. Exp Hematol 2008;36:1573-84
   PubMed Web of Science ®Google Scholar
• Kelley LL, Green WF, Hicks GG, et al. Apoptosis in erythroid progenitors deprived of erythropoietin occurs during the G1 and S phases of the cell cycle without growth arrest or stabilization of wild-type p53. Mol Cell Biol 1994;14:4183-92
   PubMed Web of Science ®Google Scholar
• Koury MJ, Bondurant MC. Maintenance by erythropoietin of viability and maturation of murine erythroid precursor cells. J Cell Physiol 1988;137:65-74
   PubMed Web of Science ®Google Scholar
• Mikhail A. Profile of peginesatide and its potential for the treatment of anemia in adults with chronic kidney disease who are on dialysis. J Blood Med 2012;3:25-31
   PubMedGoogle Scholar
• Iain C Macdougall. New anemia therapies: translating novel strategies from bench to bedside. Am J Kidney Dis 2012;59(3):444–51
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361(21):2019-32
   PubMed Web of Science ®Google Scholar
• Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355(20):2085-98
   PubMed Web of Science ®Google Scholar
• Bunn HF. Erythropoietin. Cold Spring Harb Perspect Med 2013;3(3):a011619
   PubMed Web of Science ®Google Scholar